Coleman RL - Search Results

1

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Oza AM, et al. Among authors: coleman rl. Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4. Gynecol Oncol. 2017. PMID: 28882436 Free article. Clinical Trial.

2

Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy.

Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Burke TW, et al. Among authors: coleman rl. Gynecol Oncol. 1995 May;57(2):215-20. doi: 10.1006/gyno.1995.1128. Gynecol Oncol. 1995. PMID: 7729737 Clinical Trial.

3

Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy.

Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Coleman RL, et al. Gynecol Oncol. 1994 Oct;55(1):29-35. doi: 10.1006/gyno.1994.1242. Gynecol Oncol. 1994. PMID: 7959262

4

In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.

von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. von Gruenigen VE, et al. Among authors: coleman rl. Gynecol Oncol. 1998 Jun;69(3):197-204. doi: 10.1006/gyno.1998.5010. Gynecol Oncol. 1998. PMID: 9648587

5

Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.

Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Schorge JO, et al. Among authors: coleman rl. Gynecol Oncol. 2001 Nov;83(2):383-7. doi: 10.1006/gyno.2001.6431. Gynecol Oncol. 2001. PMID: 11606101

6

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.

Munkarah AR, Coleman RL. Munkarah AR, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018. Gynecol Oncol. 2004. PMID: 15491746 Review.

7

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

8

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Rao GG, et al. Among authors: coleman rl. Gynecol Oncol. 2005 Jan;96(1):168-72. doi: 10.1016/j.ygyno.2004.09.009. Gynecol Oncol. 2005. PMID: 15589596 Clinical Trial.

9

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Coleman RL, et al. Gynecol Oncol. 2006 Apr;101(1):126-31. doi: 10.1016/j.ygyno.2005.09.041. Epub 2005 Nov 3. Gynecol Oncol. 2006. PMID: 16271384 Clinical Trial.

10

The role of maintenance therapy and novel taxanes in ovarian cancer.

Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. Herzog TJ, et al. Among authors: coleman rl. Gynecol Oncol. 2006 Aug;102(2):218-25. doi: 10.1016/j.ygyno.2005.12.001. Epub 2006 Feb 7. Gynecol Oncol. 2006. PMID: 16460787 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

613 results

Search Page

Filters